An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index

Zachary S. Wallace, Arezou Khosroshahi, Mollie D. Carruthers, Cory A. Perugino, Hyon Choi, Corrado Campochiaro, Emma L. Culver, Frank Cortazar, Emanuel Della-torre, Mikael Ebbo, Ana Fernandes, Luca Frulloni, Phil A. Hart, Omer Karadag, Shigeyuki Kawa, Mitsuhiro Kawano, Myung Hwan Kim, Marco Lanzillotta, Shoko Matsui, Kazuichi OkazakiJay H Ryu, Takako Saeki, Nicolas Schleinitz, Paula Tanasa, Hisanori Umehara, George Webster, Wen Zhang, John H. Stone

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ, leading to organ dysfunction and failure. The IgG4-RD Responder Index (RI) was developed to help investigators assess the efficacy of treatment in a structured manner. The aim of this study was to validate the RI in a multinational investigation. Methods: The RI guides investigators through assessments of disease activity and damage in 25 domains, incorporating higher weights for disease manifestations that require urgent treatment or that worsen despite treatment. After a training exercise, investigators reviewed 12 written IgG4-RD vignettes based on real patients. Investigators calculated both an RI score as well as a physician's global assessment (PhGA) score for each vignette. In a longitudinal assessment, 3 investigators used the RI in 15 patients with newly active disease who were followed up over serial visits after treatment. We assessed interrater and intrarater reliability, precision, validity, and responsiveness. Results: The 26 physician investigators included representatives from 6 specialties and 9 countries. The interrater and intrarater reliability of the RI was strong (0.89 and 0.69, respectively). Correlations (construct validity) between the RI and PhGA were high (Spearman's r = 0.9, P < 0.0001). The RI was sensitive to change (discriminant validity). Following treatment, there was significant improvement in the RI score (mean change 10.5 [95% confidence interval (95% CI) 5.4–12], P < 0.001), which correlated with the change in the PhGA. Urgent disease and damage were captured effectively. Discussion: In this international, multispecialty study, we observed that the RI is a valid and reliable disease activity assessment tool that can be used to measure response to therapy.

Original languageEnglish (US)
Pages (from-to)1671-1678
Number of pages8
JournalArthritis Care and Research
Volume70
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Validation Studies
Immunoglobulin G
Research Personnel
Physicians
Therapeutics
Reproducibility of Results
Confidence Intervals
Exercise
Weights and Measures

ASJC Scopus subject areas

  • Rheumatology

Cite this

Wallace, Z. S., Khosroshahi, A., Carruthers, M. D., Perugino, C. A., Choi, H., Campochiaro, C., ... Stone, J. H. (2018). An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. Arthritis Care and Research, 70(11), 1671-1678. https://doi.org/10.1002/acr.23543

An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. / Wallace, Zachary S.; Khosroshahi, Arezou; Carruthers, Mollie D.; Perugino, Cory A.; Choi, Hyon; Campochiaro, Corrado; Culver, Emma L.; Cortazar, Frank; Della-torre, Emanuel; Ebbo, Mikael; Fernandes, Ana; Frulloni, Luca; Hart, Phil A.; Karadag, Omer; Kawa, Shigeyuki; Kawano, Mitsuhiro; Kim, Myung Hwan; Lanzillotta, Marco; Matsui, Shoko; Okazaki, Kazuichi; Ryu, Jay H; Saeki, Takako; Schleinitz, Nicolas; Tanasa, Paula; Umehara, Hisanori; Webster, George; Zhang, Wen; Stone, John H.

In: Arthritis Care and Research, Vol. 70, No. 11, 01.11.2018, p. 1671-1678.

Research output: Contribution to journalArticle

Wallace, ZS, Khosroshahi, A, Carruthers, MD, Perugino, CA, Choi, H, Campochiaro, C, Culver, EL, Cortazar, F, Della-torre, E, Ebbo, M, Fernandes, A, Frulloni, L, Hart, PA, Karadag, O, Kawa, S, Kawano, M, Kim, MH, Lanzillotta, M, Matsui, S, Okazaki, K, Ryu, JH, Saeki, T, Schleinitz, N, Tanasa, P, Umehara, H, Webster, G, Zhang, W & Stone, JH 2018, 'An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index', Arthritis Care and Research, vol. 70, no. 11, pp. 1671-1678. https://doi.org/10.1002/acr.23543
Wallace ZS, Khosroshahi A, Carruthers MD, Perugino CA, Choi H, Campochiaro C et al. An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. Arthritis Care and Research. 2018 Nov 1;70(11):1671-1678. https://doi.org/10.1002/acr.23543
Wallace, Zachary S. ; Khosroshahi, Arezou ; Carruthers, Mollie D. ; Perugino, Cory A. ; Choi, Hyon ; Campochiaro, Corrado ; Culver, Emma L. ; Cortazar, Frank ; Della-torre, Emanuel ; Ebbo, Mikael ; Fernandes, Ana ; Frulloni, Luca ; Hart, Phil A. ; Karadag, Omer ; Kawa, Shigeyuki ; Kawano, Mitsuhiro ; Kim, Myung Hwan ; Lanzillotta, Marco ; Matsui, Shoko ; Okazaki, Kazuichi ; Ryu, Jay H ; Saeki, Takako ; Schleinitz, Nicolas ; Tanasa, Paula ; Umehara, Hisanori ; Webster, George ; Zhang, Wen ; Stone, John H. / An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. In: Arthritis Care and Research. 2018 ; Vol. 70, No. 11. pp. 1671-1678.
@article{59ab061ff2304e99b7a5e2688514d423,
title = "An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index",
abstract = "Objective: IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ, leading to organ dysfunction and failure. The IgG4-RD Responder Index (RI) was developed to help investigators assess the efficacy of treatment in a structured manner. The aim of this study was to validate the RI in a multinational investigation. Methods: The RI guides investigators through assessments of disease activity and damage in 25 domains, incorporating higher weights for disease manifestations that require urgent treatment or that worsen despite treatment. After a training exercise, investigators reviewed 12 written IgG4-RD vignettes based on real patients. Investigators calculated both an RI score as well as a physician's global assessment (PhGA) score for each vignette. In a longitudinal assessment, 3 investigators used the RI in 15 patients with newly active disease who were followed up over serial visits after treatment. We assessed interrater and intrarater reliability, precision, validity, and responsiveness. Results: The 26 physician investigators included representatives from 6 specialties and 9 countries. The interrater and intrarater reliability of the RI was strong (0.89 and 0.69, respectively). Correlations (construct validity) between the RI and PhGA were high (Spearman's r = 0.9, P < 0.0001). The RI was sensitive to change (discriminant validity). Following treatment, there was significant improvement in the RI score (mean change 10.5 [95{\%} confidence interval (95{\%} CI) 5.4–12], P < 0.001), which correlated with the change in the PhGA. Urgent disease and damage were captured effectively. Discussion: In this international, multispecialty study, we observed that the RI is a valid and reliable disease activity assessment tool that can be used to measure response to therapy.",
author = "Wallace, {Zachary S.} and Arezou Khosroshahi and Carruthers, {Mollie D.} and Perugino, {Cory A.} and Hyon Choi and Corrado Campochiaro and Culver, {Emma L.} and Frank Cortazar and Emanuel Della-torre and Mikael Ebbo and Ana Fernandes and Luca Frulloni and Hart, {Phil A.} and Omer Karadag and Shigeyuki Kawa and Mitsuhiro Kawano and Kim, {Myung Hwan} and Marco Lanzillotta and Shoko Matsui and Kazuichi Okazaki and Ryu, {Jay H} and Takako Saeki and Nicolas Schleinitz and Paula Tanasa and Hisanori Umehara and George Webster and Wen Zhang and Stone, {John H.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1002/acr.23543",
language = "English (US)",
volume = "70",
pages = "1671--1678",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index

AU - Wallace, Zachary S.

AU - Khosroshahi, Arezou

AU - Carruthers, Mollie D.

AU - Perugino, Cory A.

AU - Choi, Hyon

AU - Campochiaro, Corrado

AU - Culver, Emma L.

AU - Cortazar, Frank

AU - Della-torre, Emanuel

AU - Ebbo, Mikael

AU - Fernandes, Ana

AU - Frulloni, Luca

AU - Hart, Phil A.

AU - Karadag, Omer

AU - Kawa, Shigeyuki

AU - Kawano, Mitsuhiro

AU - Kim, Myung Hwan

AU - Lanzillotta, Marco

AU - Matsui, Shoko

AU - Okazaki, Kazuichi

AU - Ryu, Jay H

AU - Saeki, Takako

AU - Schleinitz, Nicolas

AU - Tanasa, Paula

AU - Umehara, Hisanori

AU - Webster, George

AU - Zhang, Wen

AU - Stone, John H.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Objective: IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ, leading to organ dysfunction and failure. The IgG4-RD Responder Index (RI) was developed to help investigators assess the efficacy of treatment in a structured manner. The aim of this study was to validate the RI in a multinational investigation. Methods: The RI guides investigators through assessments of disease activity and damage in 25 domains, incorporating higher weights for disease manifestations that require urgent treatment or that worsen despite treatment. After a training exercise, investigators reviewed 12 written IgG4-RD vignettes based on real patients. Investigators calculated both an RI score as well as a physician's global assessment (PhGA) score for each vignette. In a longitudinal assessment, 3 investigators used the RI in 15 patients with newly active disease who were followed up over serial visits after treatment. We assessed interrater and intrarater reliability, precision, validity, and responsiveness. Results: The 26 physician investigators included representatives from 6 specialties and 9 countries. The interrater and intrarater reliability of the RI was strong (0.89 and 0.69, respectively). Correlations (construct validity) between the RI and PhGA were high (Spearman's r = 0.9, P < 0.0001). The RI was sensitive to change (discriminant validity). Following treatment, there was significant improvement in the RI score (mean change 10.5 [95% confidence interval (95% CI) 5.4–12], P < 0.001), which correlated with the change in the PhGA. Urgent disease and damage were captured effectively. Discussion: In this international, multispecialty study, we observed that the RI is a valid and reliable disease activity assessment tool that can be used to measure response to therapy.

AB - Objective: IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ, leading to organ dysfunction and failure. The IgG4-RD Responder Index (RI) was developed to help investigators assess the efficacy of treatment in a structured manner. The aim of this study was to validate the RI in a multinational investigation. Methods: The RI guides investigators through assessments of disease activity and damage in 25 domains, incorporating higher weights for disease manifestations that require urgent treatment or that worsen despite treatment. After a training exercise, investigators reviewed 12 written IgG4-RD vignettes based on real patients. Investigators calculated both an RI score as well as a physician's global assessment (PhGA) score for each vignette. In a longitudinal assessment, 3 investigators used the RI in 15 patients with newly active disease who were followed up over serial visits after treatment. We assessed interrater and intrarater reliability, precision, validity, and responsiveness. Results: The 26 physician investigators included representatives from 6 specialties and 9 countries. The interrater and intrarater reliability of the RI was strong (0.89 and 0.69, respectively). Correlations (construct validity) between the RI and PhGA were high (Spearman's r = 0.9, P < 0.0001). The RI was sensitive to change (discriminant validity). Following treatment, there was significant improvement in the RI score (mean change 10.5 [95% confidence interval (95% CI) 5.4–12], P < 0.001), which correlated with the change in the PhGA. Urgent disease and damage were captured effectively. Discussion: In this international, multispecialty study, we observed that the RI is a valid and reliable disease activity assessment tool that can be used to measure response to therapy.

UR - http://www.scopus.com/inward/record.url?scp=85055417294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055417294&partnerID=8YFLogxK

U2 - 10.1002/acr.23543

DO - 10.1002/acr.23543

M3 - Article

C2 - 29457382

AN - SCOPUS:85055417294

VL - 70

SP - 1671

EP - 1678

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 11

ER -